BOLD stock forecast
Our latest prediction for Audentes Therapeutics, Inc.'s stock price was made on the Sept. 18, 2018 when the stock price was at 40.05$.
In the short term (2weeks), BOLD's stock price should outperform the market by 0.02%. During that period the price should oscillate between -8.13% and +9.40%.
In the medium term (3months), BOLD's stock price should outperform the market by 0.28%. During that period the price should oscillate between -17.90% and +26.04%.Get email alerts
About Audentes Therapeutics, Inc.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.38$ per share.
The book value per share is 9.13$
Three months stock forecastSept. 18, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|